CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of SYH2062 injection in healthy Chinese volunteers

评价SYH2062注射液在中国健康受试者中单次皮下注射给药的安全性和耐受性。次要目的：评价SYH2062注射液在中国健康受试者中单次皮下注射给药的药代动力学（PK）、药效动力学（PD ）特征；评价 SYH2062 注射液在中国健康受试者中单次皮下注射给药后生物标志物表达水平的变化特征；评价SYH2062注射液在中国健康受试者中单次皮下注射给药的免疫原性特征。

Daunorubicin, Cytarabine Liposomes(CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.) is a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a fixed 5:1 synergistic molar ratio.
This is a phase 2, randomized, controlled study in patients who are >= 18 or more years old and have not been treated before. Participants who take part in this study should not be suitable for intensive induction therapy.
In this study, patients will be randomized by 1:1:1 to receive Daunorubicin, Cytarabine Liposomes + Venetoclax(14d) or Daunorubicin, Cytarabine Liposomes + Venetoclax(21d) or Venetoclax + Azacitidine.
Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit.